Head-to-head · WeighScore
Invyncible vs Midi Health
The verdict
Invyncible takes it — 61/100 to 56.4/100.
Invyncible grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Invyncible is a Florida-based telehealth platform offering semaglutide and tirzepatide programs for weight management.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Invyncible | Midi Health |
|---|---|---|
| WeighScore | 61/100 | 56.4/100 |
| Grade | C | C |
| Scorecard rank | #303 | #413 |
| Semaglutide | $192/mo (0.5 mg dose, compounded) | Not disclosed |
| Tirzepatide | $210/mo (compounded) | Not disclosed |
| Coverage | 40 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #303 · C
Strengths
- Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
- Physical corporate address published (St. Petersburg, FL)
- LegitScript verification seal displayed
- No long-term commitment required
- Offers both semaglutide and tirzepatide programs
Where it loses points
- Pricing not disclosed on the public site — fully gated behind signup
- Drug forms (compounded vs brand, injection vs oral) not disclosed
- 503A vs 503B designation not specified
- Pharmacy partner not named
- States served not listed publicly
Graded #413 · C
Strengths
- Available in all 50 states
- Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
- Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
- Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)
Where it loses points
- Does not accept Medicare, Medicaid, or Medi-Cal
- GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
- Menopause-focused — not the right fit for men or younger women whose main goal is weight loss
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.